mRNA Flu Vaccine Faces FDA Verdict: Approval Alone Won't Mean Coverage for Seniors

mRNA flu vaccine mFlusiva faces its FDA decision deadline today. Approval will not automatically trigger insurance coverage for patients -- that requires an ACIP recommendation that a March 2026 federal court ruling has made impossible to issue. For adults 65+, head-to-head evidence against Fluzone High-Dose remains incomplete.